This approach enabled us to identify several novel and promising rhabdomyosarcoma CSC-specific targets, e.g., ALDH6A1, SOX4, PAX3, CDH15, downregulated MIR145, or phosphorylated RYK, which warrant validation in subsequent mechanistic studies. The gene discussed is RYK; the disease is rhabdomyosarcoma.